Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) with an autoimmune mechanism of development. Currently, one of the most promising directions in the study of MS pathogenesis are the neuroimmune interactions. Dopamine is one of the key neurotransmitters in CNS. Furthermore, dopamine is a direct mediator of interactions between the immune and nervous systems and can influence MS pathogenesis by modulating immune cells activity and cytokine production. Recent studies have shown that dopamine can enhance or inhibit the functions of innate and adaptive immune system, depending on the activation of different dopaminergic receptors, and can therefore influence the course of experimental autoimmune encephalomyelitis (EAE) and MS. In this review, we discuss putative dopaminergic therapeutics in EAE and MS with focus on Th17-cells, which are thought to play crucial role in MS pathogenesis. We suggest that targeting dopaminergic receptors could be explored as a new kind of disease-modifying treatment of MS.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarenga-Filho H, Sacramento PM, Ferreira TB, Hygino J, Abreu JE, Carvalho SR, Wing AC, Alvarenga RM, Bento CA (2016) Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators. J Neuroimmunol 293:91–99. https://doi.org/10.1016/j.jneuroim.2016.02.014
Arreola R, Alvarez-Herrera S, Perez-Sanchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez EO, Garces-Alvarez ME, de la Cruz-Aguilera DL, Medina-Rivero E, Hurtado-Alvarado G, Quintero-Fabian S, Pavon L (2016) Immunomodulatory Effects Mediated by Dopamine. J Immunol Res, 2016: 3160486. https://doi.org/10.1155/2016/3160486
Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, Azizi G, Baradaran B (2017) The paradox of Th17 cell functions in tumor immunity. Cell Immunol 322:15–25. https://doi.org/10.1016/j.cellimm.2017.10.015
Basdeo SA, Cluxton D, Sulaimani J, Moran B, Canavan M, Orr C, Veale DJ, Fearon U, Fletcher JM (2017) Ex-Th17 (nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells. J Immunol 198(6):2249–2259. https://doi.org/10.4049/jimmunol.1600737
Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217. https://doi.org/10.1124/pr.110.002642
Bellavista E, Santoro A, Galimberti D, Comi C, Luciani F, Mishto M (2014) Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. Autoimmune Dis 2014:739705. https://doi.org/10.1155/2014/739705
Boyko A, Melnikov M, Zhetishev R, Pashenkov M (2016) The role of biogenic amines in regulation of interaction between immune and nervous systems in multiple sclerosis. Neuroimmunomodulation 23(4):217–223. https://doi.org/10.1159/000449167
Broos CE, Koth LL, van Nimwegen M, In’t Veen JCCM, SMJ P, van Hamburg JP, Annema JT, Heller-Baan R, Kleinjan A, Hoogsteden HC, Wijsenbeek MS, Hendriks RW, van den Blink B, Kool M (2018) Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J 51(3):1701124. https://doi.org/10.1183/13993003.01124-2017
Cao Y, Goods BA, Raddassi K, Nepom GT, Kwok WW, Love JC, Hafler DA (2015) Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med 7(287):287ra74. https://doi.org/10.1126/scitranslmed.aaa8038
Castaneda AR, Pinkerton KE, Bein KJ, Magana-Méndez A, Yang HT, Ashwood P, Vogel CFA (2018) Ambient particulate matter activates the aryl hydrocarbon receptor in DCs and enhances Th17 polarization. Toxicol Lett 292:85–96. https://doi.org/10.1016/j.toxlet.2018.04.020
Caza T, Landas S (2015) Functional and phenotypic plasticity of CD4(+) T cell subsets. Biomed Res Int 2015:521957. https://doi.org/10.1155/2015/521957
Chen G, Shannon MF (2013) Transcription factors and th17 cell development in experimental autoimmune encephalomyelitis. Crit Rev Immunol 33(2):165–182
Chyuan IT, Chen JY (2018) Role of interleukin-(IL-) 17 in the pathogenesis and targeted therapies in Spondyloarthropathies. Mediat Inflamm 2018:2403935. https://doi.org/10.1155/2018/2403935
Contreras F, Prado C, Gonzalez H, Franz D, Osorio-Barrios F, Osorio F, Ugalde V, Lopez E, Elgueta D, Figueroa A, Lladser A, Pacheco R (2016) Dopamine receptor D3 signaling on CD4+ T cells favors Th1- and Th17-mediated immunity. J Immunol 196:4143–4149. https://doi.org/10.4049/jimmunol.1502420
Cosentino M, Marino F (2013) Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J NeuroImmune Pharmacol 8(1):163–179. https://doi.org/10.1007/s11481-012-9410-z
Cosentino M, Zaffaroni M, Marino F, Bombelli R, Ferrari M, Rasini E, Lecchini S, Ghezzi A, Frigo G (2002) Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol 133(1–2):233–240
Cosentino M, Zaffaroni M, Ferrari M, Marino F, Bombelli R, Rasini E, Frigo G, Ghezzi A, Comi G, Lecchini S (2005) Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J Neuroimmunol 162:112–121
Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F (2012) Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy. Neuroimmunomodulation. 19(5):283–292. https://doi.org/10.1159/000336981
Cosentino M, Zaffaroni M, Marino F (2014) Levels of mRNA for dopaminergic receptor D5 in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis. J Neuroimmunol 277(1-2):193–196. https://doi.org/10.1016/j.jneuroim.2014.10.009
Cosentino M, Zaffaroni M, Legnaro M, Bombelli R, Schembri L, Baroncini D, Bianchi A, Clerici R, Guidotti M, Banfi P, Bono G, Marino F (2016) Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis. J Neuroimmunol 298:82–89. https://doi.org/10.1016/j.jneuroim.2016.07.008
De Laere M, Berneman ZN, Cools N (2018) To the brain and Back: migratory paths of DCs in multiple sclerosis. J Neuropathol Exp Neurol 77(3):178–192. https://doi.org/10.1093/jnen/nlx114
Dianzani C, Bellavista E, Liepe J, Verderio C, Martucci M, Santoro A, Chiocchetti A, Gigliotti CL, Boggio E, Ferrara B, Riganti L, Keller C, Janek K, Niewienda A, Fenoglio C, Sorosina M, Cantello R, Kloetzel PM, Stumpf MP, Paul F, Ruprecht K, Galimberti D, Martinelli Boneschi F, Comi C, Dianzani U, Mishto M (2017) Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci Rep 7:43718. https://doi.org/10.1038/srep43718
Dijkstra CD, van der Voort ER, De Groot CJ, Huitinga I, Uitdehaag BM, Polman CH, Berkenbosch F (1994) Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 19(2):135–142
Dobson R, Ramagopalan S, Davis A, Giovannoni G (2013) Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 84(8):909–914. https://doi.org/10.1136/jnnp-2012-304695
Escribano BM, Aguilar-Luque M, Bahamonde C, Conde C, Lillo R, Sanchez-Lopez F, Giraldo AI, Cruz AH, Luque E, Gascon F, Aguera E, Tunez I (2016) Natalizumab modifies Catecholamines levels present in patients with relapsing- remitting multiple sclerosis. Curr Pharm Des 22(31):4876–4880
Estes ML, McAllister AK (2016) IMMUNOLOGY. Maternal TH17 cells take a toll on baby's brain. Science 351(6276):919–920. https://doi.org/10.1126/science.aaf2850
Ferreira TB, Kasahara TM, Barros PO, Vieira MM, Bittencourt VC, Hygino J, Andrade RM, Linhares UC, Andrade AF, Bento CA (2011) Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder. J Neuroimmunol 238(1-2):58–66. https://doi.org/10.1016/j.jneuroim.2011.06.009
Ferreira TB, Barros PO, Teixeira B, Cassano T, Centurião N, Kasahara TM, Hygino J, Vasconcelos CC, Filho HA, Alvarenga R, Wing AC, Andrade RM, Andrade AF, Bento CA (2014) Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis. Brain Behav Immun 41:182–190. https://doi.org/10.1016/j.bbi.2014.05.013
Franz D, Contreras F, Gonzalez H, Prado C, Elgueta D, Figueroa C, Pacheco R (2015) Dopamine receptors D3 and D5 regulate CD4(+)T-cell activation and differentiation by modulating ERK activation and cAMP production. J Neuroimmunol 284:18–29. https://doi.org/10.1016/j.jneuroim.2015.05.003
Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR (2007) Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 6(3):169–175
Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523(7559):221–225. https://doi.org/10.1038/nature14452
Giorelli M, Livrea P, Trojano M (2005) Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J Interf Cytokine Res 25(7):395–406
Goepfert A, Lehmann S, Wirth E, Rondeau JM (2017) The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Sci Rep 7(1):8906. https://doi.org/10.1038/s41598-017-08360-9
Goldstein DS, Holmes C (2008) Neuronal source of plasma dopamine. Clin Chem 54:1864–1871. https://doi.org/10.1373/clinchem.2008.107193
Gong S, Li J, Ma L, Li K, Zhang L, Wang G, Liu Y, Ji X, Liu X, Chen P, Ouyang R, Zhang S, Zhou Z, Wang CY, Xiang X, Yang Y (2013) Blockade of dopamine D1-like receptor signalling protects mice against OVA-induced acute asthma by inhibiting B-cell activating transcription factor signalling and Th17 function. FEBS J 280(23):6262–6273. https://doi.org/10.1111/febs.12549
Hashimoto K, Inoue T, Higashi T, Takei S, Awata T, Katayama S, Takagi R, Okada H, Matsushita S (2009) Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice. Biochem Biophys Res Commun 383(4):460–463. https://doi.org/10.1016/j.bbrc.2009.04.034
Hauser SL (2015) The Charcot lecture: beating MS: a story of B cells, with twists and turns. Mult Scler 21(1):8–21
Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204(12):2803–2812. https://doi.org/10.1084/jem.20071397
Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13:1173–1175. https://doi.org/10.1038/nm1651
Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S (2010) A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 67(9):1055–1061. https://doi.org/10.1001/archneurol.2010.222
Kolbinger F, Huppertz C, Mir A, Padova FD (2016) IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous system. Curr Drug Targets 17(16):1882–1893
Kustrimovic N, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Comi C, Mauri M, Minafra B, Riboldazzi G, Sanchez-Guajardo V, Marino F, Cosentino M (2016) Dopaminergic receptors on CD4+ T naive and memory lymphocytes correlate with motor impairment in patients with Parkinson's disease. Sci Rep 6:33738. https://doi.org/10.1038/srep33738
Lee GR (2018) The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci 19(3):E730. https://doi.org/10.3390/ijms19030730
Lee PW, Yang Y, Racke MK, Lovett-Racke AE (2015) Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: implications for multiple sclerosis. Brain Behav Immun 46:44–49. https://doi.org/10.1016/j.bbi.2014.12.007
Levite M (2016) Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol (Oxford) 216(1):42–89. https://doi.org/10.1111/apha.12476
Levite M, Marino F, Cosentino M (2017) Dopamine, T cells and multiple sclerosis (MS). J Neural Transm (Vienna) 124(5):525–542. https://doi.org/10.1007/s00702-016-1640-4
Ley S, Weigert A, Brune B (2010) Neuromediators in inflammation--a macrophage/nerve connection. Immunobiology. 215:674–684. https://doi.org/10.1016/j.imbio.2010.05.027
Lieberknecht V, Junqueira SC, Cunha MP, Barbosa TA, de Souza LF, Coelho IS, Santos AR, Rodrigues AL, Dafré AL, Dutra RC (2017) Pramipexole, a dopamine D2/D3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis development in mice. Mol Neurobiol 54(2):1033–1045. https://doi.org/10.1007/s12035-016-9717-5
Liu H, Leak RK, Hu X (2016) Neurotransmitter receptors on microglia. Stroke Vasc Neurol 1:52–58. https://doi.org/10.1136/svn-2016-000012
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560):337–341. https://doi.org/10.1038/nature14432
Lovett-Racke AE, Yang Y, Racke MK (2011) Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 1812(2):246–251. https://doi.org/10.1016/j.bbadis.2010.05.012
Lu MY, Lu SS, Chang SL, Liao F (2018) The phosphorylation of ccr6 on distinct ser/Thr residues in the carboxyl terminus differentially regulates biological function. Front Immunol 9:415. https://doi.org/10.3389/fimmu.2018.00415
Mailer RKW (2018) Alternative splicing of FOXP3-virtue and vice. Front Immunol 9:530. https://doi.org/10.3389/fimmu.2018.00530
Marino F, Cosentino M (2016) Multiple sclerosis: repurposing dopaminergic drugs for MS--the evidence mounts. Nat Rev Neurol 12(4):191–192. https://doi.org/10.1038/nrneurol.2016.33
Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Karahalios G, Sfagos C (2009) Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J Neurochem 108(1):158–164. https://doi.org/10.1111/j.1471-4159.2008.05750.x
Mbongue J, Nicholas D, Firek A, Langridge W (2014) The role of DCs in tissue-specific autoimmunity. J Immunol Res 2014:857143–857117. https://doi.org/10.1155/2014/857143
McGinley AM, Edwards SC, Raverdeau M, Mills KH (2018) Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. J Autoimmun S0896–8411(18)30007–6. https://doi.org/10.1016/j.jaut.2018.01.001
Melnikov M, Belousova O, Murugin V, Pashenkov M, Boyko A (2016) The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J Neuroimmunol 292:97–101. https://doi.org/10.1016/j.jneuroim.2016.01.020
Melnikov M, Rogovskii V, Boyko A, Pashenkov M (2018) The influence of biogenic amines on Th17-mediated immune response in multiple sclerosis. Mult Scler Relat Disord 21:19–23. https://doi.org/10.1016/j.msard.2018.02.012
Mojic M, Takeda K, Hayakawa Y (2017) The dark side of IFN-gamma: its role in promoting Cancer Immunoevasion. Int J Mol Sci 19(1). https://doi.org/10.3390/ijms19010089
Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79(9):1027–1031
Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, Baker GB, Kerr BJ (2011) The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun 25(8):1677–1688. https://doi.org/10.1016/j.bbi.2011.06.011
Nakagome K, Imamura M, Okada H, Kawahata K, Inoue T, Hashimoto K, Harada H, Higashi T, Takagi R, Nakano K, Hagiwara K, Kanazawa M, Dohi M, Nagata M, Matsushita S (2011) Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 186(10):5975–5982. https://doi.org/10.4049/jimmunol.1001274
Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S (2008) Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373(]): 286-291. https://doi.org/10.1016/j.bbrc.2008.06.012
Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S (2009) Dopamine released by DCs polarizes Th2 differentiation. Int Immunol 21(6):645–654. https://doi.org/10.1093/intimm/dxp033
Nakano K, Yamaoka K, Hanami K, Saito K (2011) Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/ SCID mouse chimera model. J Immunol 186(6):3745–3752. https://doi.org/10.4049/jimmunol.1002475
Okada H, Inoue T, Hashimoto K, Suzuki H, Matsushita S (2009) D1-like receptor antagonist inhibits IL-17 expression and attenuates crescent formation in nephrotoxic serum nephritis. Am J Nephrol 30(3):274–279. https://doi.org/10.1159/000225902
Oleskin AV, Shenderov BA, Rogovsky VS (2017) Role of neurochemicals in the interaction between the microbiota and the immune and the nervous system of the host organism. Probiotics Antimicrob Proteins 9:215–234. https://doi.org/10.1007/s12602-017-9262-1
Omenetti S, Pizarro TT (2015) The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol 6:639. https://doi.org/10.3389/fimmu.2015.00639
Osorio-Barrios F, Prado C, Contreras F, Pacheco R (2018) Dopamine receptor D5 signaling plays a dual role in experimental autoimmune encephalomyelitis potentiating Th17-mediated immunity and favoring suppressive activity of regulatory T-cells. Front Cell Neurosci 12:192. https://doi.org/10.3389/fncel.2018.00192
Pacheco R, Prado CE, Barrientos MJ, Bernales S (2009) Role of dopamine in the physiology of T-cells and DCs. J Neuroimmunol 216(1-2):8–19. https://doi.org/10.1016/j.jneuroim.2009.07.018
Pacheco R, Contreras F, Zouali M (2014) The dopaminergic system in autoimmune diseases. Front Immunol 5:117. https://doi.org/10.3389/fimmu.2014.00117
Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37(7):1097–1102
Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H (2001) Two subsets of DCs are present in human cerebrospinal fluid. Brain 124(Pt 3):480–492
Passos GRD, Sato DK, Becker J (2016) Fujihara K (2016) Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications. Mediat Inflamm 2016:5314541–5314511. https://doi.org/10.1155/2016/5314541
Pinoli M, Marino F, Cosentino M (2017) Dopaminergic regulation of innate immunity: a review. J NeuroImmune Pharmacol 12(4):602–623. https://doi.org/10.1007/s11481-017-9749-2
Polak ME, Kalinin S, Feinstein DL (2011) Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 134(Pt 3):665–677. https://doi.org/10.1093/brain/awq362
Pötzl J, Botteron C, Tausch E, Pedré X, Mueller AM, Männel DN, Lechner A (2008) Tracing functional antigen-specific CCR6 Th17 cells after vaccination. PLoS One 3(8):e2951. https://doi.org/10.1371/journal.pone.0002951
Prado C, Contreras F, González H, Díaz P, Elgueta D, Barrientos M, Herrada AA, Lladser Á, Bernales S, Pacheco R (2012) Stimulation of dopamine receptor D5 expressed on DCs potentiates Th17-mediated immunity. J Immunol 188(7):3062–3070. https://doi.org/10.4049/jimmunol.1103096
Prado C, Gaiazzi M, González H, Ugalde V, Figueroa A, Osorio-Barrios FJ, López E, Lladser A, Rasini E, Marino F, Zaffaroni M, Cosentino M, Pacheco R (2018) Dopaminergic stimulation of myeloid antigen-presenting cells attenuates signal transducer and activator of transcription 3-activation Favouring the development of experimental autoimmune encephalomyelitis. Front Immunol 9:571. https://doi.org/10.3389/fimmu.2018.00571
Rajda C, Bencsik K, Vécsei L, Bergquist J (2002) Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. Neuroimmunol 124(1-2):93–100
Rajda C, Bencsik K, Füvesi J, Seres E, Vécsei L, Bergquist J (2006) The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult Scler 12(3):265–270
Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10(5):514–523. https://doi.org/10.1038/ni.1716
Restorick SM, Durant L, Kalra S, Hassan-Smith G, Rathbone E, Douglas MR, Curnow SJ (2017) CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav Immun 64:71–79. https://doi.org/10.1016/j.bbi.2017.03.008
Rogovskii VS (2017) The linkage between inflammation and immune tolerance: interfering with inflammation in Cancer. Curr Cancer Drug Targets 17:325–332. https://doi.org/10.2174/1568009617666170109110816
Rostami A, Ciric B (2017) Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 333(1-2):76–87. https://doi.org/10.1016/j.jns.2013.03.002
Sabatino JJ Jr, Zamvil SS (2017) Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity. Neurol Neuroimmunol Neuroinflamm 4(4):e366. https://doi.org/10.1212/NXI.0000000000000366
Sie C, Korn T (2016) DCs in central nervous system autoimmunity. Semin Immunopathol 39(2):99–111. https://doi.org/10.1007/s00281-016-0608-7
Simpson S Jr, Stewart N, van der Mei I, Otahal P, Charlesworth J, Ponsonby AL, Blizzard L, Dwyer T, Pittas F, Gies P, Taylor B (2015) Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. J Neurol Neurosurg Psychiatry 86(2):200–207. https://doi.org/10.1136/jnnp-2013-307336
Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180:214–221. https://doi.org/10.4049/jimmunol.180.1.214
Stockinger B, Omenetti S (2017) The dichotomous nature of T helper 17 cells. Nat Rev Immunol 17(9):535–544. https://doi.org/10.1038/nri.2017.50
Sun L, Fu J, Zhou Y (2017) Metabolism controls the balance of Th17/T-regulatory cells. Front Immunol 8:1632. https://doi.org/10.3389/fimmu.2017.01632
Tai Y, Wang Q, Korner H, Zhang L, Wei W (2018) Molecular mechanisms of T cells activation by DCs in autoimmune diseases. Front Pharmacol 9:642. https://doi.org/10.3389/fphar.2018.00642
Talhada D, Rabenstein M, Ruscher K (2018) The role of dopaminergic immune cell signalling in poststroke inflammation. Ther Adv Neurol Disord 11:1756286418774225. https://doi.org/10.1177/1756286418774225
Vallone D, Picetti R, Borrelli E (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24(1):125–132. https://doi.org/10.1016/S0149-7634(99)00063-9
van Langelaar J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, Spilt IM, Siepman TA, Dankers W, Verjans GMGM, de Vries HE, Lubberts E, Hintzen RQ, van Luijn MM (2018) T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain 141(5):1334–1349. https://doi.org/10.1093/brain/awy069
Wang T, Nowrangi D, Yu L, Lu T, Tang J, Han B, Ding Y, Fu F, Zhang JH (2018) Activation of dopamine D1 receptor decreased NLRP3-mediated inflammation in intracerebral hemorrhage mice. J Neuroinflammation 15:2. https://doi.org/10.1186/s12974-017-1039-7
Wojkowska DW, Szpakowski P, Ksiazek-Winiarek D, Leszczynski M, Glabinski A (2014) Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis. Mediat Inflamm 2014:590409–590408. https://doi.org/10.1155/2014/590409
Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M, Ghezzi A, Comi G, Lecchini S, Cosentino M (2008) Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol 214(2):315–321. https://doi.org/10.1016/j.expneurol.2008.08.015
Zhang X, Liu Q, Liao Q, Zhao Y (2017) Potential roles of peripheral dopamine in tumor immunity. J Cancer 8:2966–2973. https://doi.org/10.7150/jca.20850
Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F (2012) Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484(7395):514–518. https://doi.org/10.1038/nature10957
Zozulya AL, Clarkson BD, Ortler S, Fabry Z, Wiendl H (2010) The role of DCs in CNS autoimmunity. J Mol Med (Berl) 88(6):535–544. https://doi.org/10.1007/s00109-010-0607-4
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Melnikov, M., Rogovskii, V., Boykо, A. et al. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions. J Neuroimmune Pharmacol 15, 37–47 (2020). https://doi.org/10.1007/s11481-019-09852-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-019-09852-3